Glioblastoma (GBM) is the least treatable type of brain tumor, afflicting over 15,000 people per year in the United States. Patients have a median survival of 16 months, and over 95% die within 5 years. The chemokine receptor ACKR3 is selectively expressed on both GBM cells and tumor-associated blood vessels. High tumor expression of ACKR3 correlates with poor prognosis and potential treatment resistance, making it an attractive therapeutic target. We engineered a single chain FV-human FC-immunoglobulin G1 (IgG 1 ) antibody, X7Ab, to target ACKR3 in human and mouse GBM cells. We used hydrodynamic gene transfer to overexpress the antibody, with efficacy in vivo. X7Ab kills GBM tumor cells and ACKR3-expressing vascular endothelial cells by engaging the cytotoxic activity of natural killer (NK) cells and complement and the phagocytic activity of macrophages. Combining X7Ab with TMZ allows the TMZ dosage to be lowered, without compromising therapeutic efficacy. Mice treated with X7Ab and in combination with TMZ showed significant tumor reduction by MRI and longer survival overall. Brain-tumor-infiltrating leukocyte analysis revealed that X7Ab enhances the activation of M1 macrophages to support anti-tumor immune response in vivo. Targeting ACKR3 with immunotherapeutic monoclonal antibodies (mAbs) in combination with standard of care therapies may prove effective in treating GBM.
Glioblastoma (GBM) is the least treatable type of brain tumor, afflicting over 15,000 people per year in the United States. Patients have a median survival of 16 months, and over 95% die within 5 years. The chemokine receptor ACKR3 is selectively expressed on both GBM cells and tumor-associated blood vessels. High tumor expression of ACKR3 correlates with poor prognosis and potential treatment resistance, making it an attractive therapeutic target. We engineered a single chain FV-human FC-immunoglobulin G1 (IgG 1 ) antibody, X7Ab, to target ACKR3 in human and mouse GBM cells. We used hydrodynamic gene transfer to overexpress the antibody, with efficacy in vivo. X7Ab kills GBM tumor cells and ACKR3-expressing vascular endothelial cells by engaging the cytotoxic activity of natural killer (NK) cells and complement and the phagocytic activity of macrophages. Combining X7Ab with TMZ allows the TMZ dosage to be lowered, without compromising therapeutic efficacy. Mice treated with X7Ab and in combination with TMZ showed significant tumor reduction by MRI and longer survival overall. Brain-tumor-infiltrating leukocyte analysis revealed that X7Ab enhances the activation of M1 macrophages to support anti-tumor immune response in vivo. Targeting ACKR3 with immunotherapeutic monoclonal antibodies (mAbs) in combination with standard of care therapies may prove effective in treating GBM.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer. GBM is considered incurable. With the best available care, a combination of temozolomide (TMZ) and radiotherapy (RT), the median survival for GBM is approximately 16 months, with a 5-year survival rate of 3.3%. 1 The current conventional therapy, TMZ/RT usually fails due to cancer cell resistance, and patients are next treated with Avastin, a potent anti-angiogenic antibody that also fails after approximately 5 months due to hypoxia-mediated resistance. 1 The C-X-C chemokine receptor 7 (CXCR7) ACKR3 has recently been identified across independent studies as an actionable target for treatment of GBM. [2] [3] [4] [5] [6] ACKR3 is a unique target for cancer therapy due to its overexpression on both tumor cells and tumor endothelial cells. 7, 8 ACKR3 surface protein is evident on activated endothelium or tumor tissue while low to absent on the cell surface of normal adult tissues. 9 The receptor is required for embryonic development, where it acts as a scavenger for CXCL12 to generate a gradient for proper CXCR4+ primordial germ cell migration. [10] [11] [12] [13] To evaluate the potential of targeting ACKR3 in GBM, we generated a single chain anti-ACKR3 antibody (X7Ab), with a human fragment crystallizable (huFC) domain capable of mobilizing anti-tumor innate immune defenses. We assessed X7Ab for its cellular mechanism of action against GBM. We also asked whether in combination with TMZ, X7Ab could improve survival in mouse GBM models.
RESULTS

ACKR3 in Human Glioma
High ACKR3 expression significantly correlated with poor survival in patients with high-grade glioma (astrocytomas and glioblastomas, also known as grade III and IV astrocytoma, respectively) 14 ( Figure 1A) . The overall survival in human clinical trials for GBM only (grade IV astrocytoma) did not reach statistical significance (p < 0.05) when divided by ACKR3/CXCR7 high versus low expression. However, at the 3-and 5-year survival time points for each study, ACKR3/CXCR7 high-expressing patients have consistently lower survival odds ( Figure S1 ). High ACKR3 expression significantly correlated with poor survival outcomes in TMZ/RT-treated GBM patients ( Figure 1B) . We used the TCGA database to assess ACKR3 RNA expression in normal and brain cancer tissue. ACKR3 expression was significantly elevated in lower grade glioma (LGG) and GBM compared to normal brain samples ( Figure 1C ). Expression of ACKR3-associated genes: endogenous ACKR3 ligands CXCL11 and CXCL12; CXCR4 (which also binds to CXCL12 and was reported to heterodimerize with ACKR3 15 ); CXCR3, a second receptor for CXCL11; and epidermal growth factor receptor (EGFR) (which co-localizes with ACKR3 in tumor cells 16, 17 ). To varying degrees, each of these ACKR3-related molecules was also upregulated in GBM (Figure 1C) , consistent with reports from previous glioma studies. 3, 18, 19 GBM tumor cells and tumor-associated vessels stained positive for ACKR3 protein, whereas normal brain tissue did not ( Figure 1D ) in CNS tissue sections from two primary GBM patients and one non-small cell lung cancer squamous cell carcinoma (NSCLCSC) brain metastasis patient. Although the level of ACKR3 protein staining (brown) in the primary GBM samples was not as strong as that observed in the NSCLCSC metastasis sample, the level of staining was above the background level of the normal sample, indicating ACKR3 protein expression. Thus, consistent with other reports, we found that ACKR3 is selectively expressed in GBM, and elevated ACKR3 expression correlates with poor clinical outcomes.
X7Ab Binds ACKR3
We generated an anti-ACKR3 single chain antibody (X7Ab) with a human immunoglobulin G1 (IgG 1 ) FC sequence based on the US www.moleculartherapy.org biosensor interferometry ( Figure 2B ). The binding potency (IC 50 ) of X7Ab in inhibiting fluorescently labeled anti-ACKR3 mAb binding to ACKR3 was 30 nM, as determined by competitive binding assay and flow cytometry ( Figure 2C ). X7Ab inhibited CXCL12-mediated b-arrestin2 signaling ( Figure 2D ). X7Ab also specifically stained ACKR3+ human breast cancer cell line transfectants (435-X7) but not parental 435-WT cells ( Figure S2A 20 ). X7Ab stained the human U343 glioma cell line previously shown to express endogenous ACKR3 21 and human U251 ACKR3+ transfectants (U251X7), but not parental U251-WT glioma cells. In addition to human ACKR3, X7Ab specifically recognized mouse ACKR3 because it stained mouse ACKR3/ HEK293 transfectants and E13 primitive red blood cells previously shown to express endogenous ACKR3 7 ( Figure S2B ). Mouse glioma GL261 also expressed low levels of endogenous surface ACKR3 and was stained with X7Ab. Thus, we confirmed by multiple methods that X7Ab specifically binds to ACKR3 ( Figure 2E ).
Functional In Vitro Anti-tumor Activity of X7Ab
We asked if X7Ab could kill tumor cells by antibody-mediated effects, such as antibody-dependent cell cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). We incubated various concentrations of X7Ab with tumor cells, and added various numbers of effector cells to cover a wide range of E:T ratios (indicated on figure legends). X7Ab triggered specific human peripheral blood mononu- (Figure 3D) . The X7Ab ADCC potency (EC 50 ) for the CD16-176F variant was 3.9 mg/mL and 1.8 mg/mL for the CD16-176V variant. The ADCC activity was specific for ACKR3 because the viability of U251-WT parent cells was unaffected by X7Ab ( Figure 3E ). We used the lipopolysaccharide (LPS)-activated mouse macrophage cell line RAW264.7 and the phorbol 12-myristate 13-acetate (PMA)-activated human monocytic cell line U937 as in vitro models of macrophages for ADCP. X7Ab also significantly enhanced the percentage of tumor cells engulfed by macrophages compared with negative controls (the ADCP effect was more pronounced with mouse macrophage effectors), and X7Ab-dependent phagocytosis required ACKR3 expression by the target (Figures 3F and 3G) . X7Ab alone had no specific effect on endogenous ACKR3-expressing U343 and GL261 cells or ACKR3-U251 cell viability in vitro, with a minor cytotoxic effect at the highest level of treatment on ACKR3+ U251X7 cells ( Figure S4 ), leading us to conclude that X7Ab primarily requires a FC-dependent mechanism to engage anti-tumor immune defenses. X7Ab also induced a weak but significant CDC response in U343 cells compared with FC-control ( Figure 3H ).
Combination Strategy
X7Ab-mediated ADCC combined with TMZ induced significantly more GBM cell death than either agent used alone ( Figures 3I and  3J ). This was true using human PBMC effectors ( Figure 3I ) or SCID splenocyte effectors ( Figure 3J ). As with ADCC, X7Ab-medi- CDC against U343 with rabbit serum (25%). Mean of triplicate wells ± SEM is shown, *p < 0.05 by t test. (I) Combination treatment with TMZ and X7Ab ADCC using hPBMC, E:T ratio of 100:1 (J) or mouse splenocyte (mSpleno), E:T ratio of 30:1 effectors to U251X7 targets. Tumor cells were incubated ± TMZ (6 mM) for 5 days and then subjected to ADCC (100 mg/mL X7Ab or FC-control); the data were normalized to the average of the total number of viable targets in the untreated wells (set to 100% viable cell targets). Mean of triplicate wells ± SEM is shown, *p < 0.05 by t test.
(K) CDC of TMZ and X7Ab combination. U251X7 cells were incubated ± TMZ (3 mM) ± X7Ab (30 mg/mL) in human serum (25%). Mean of triplicate wells ± SEM, *p < 0.05 by t test.
ated CDC combined with TMZ induced significantly more GBM cell death than either agent used singly ( Figure 3K ).
HDT to Overexpress X7Ab Protein In Vivo
We used hydrodynamic gene transfer (HDT) to express X7Ab recombinant antibody in vivo. The technique involves the rapid intravenous (i.v.) injection of a large volume of isotonic buffer containing plasmid DNA encoding X7Ab (or FC-control as a negative control) ( Figure 4A ). Hepatocytes take up the DNA and transiently overexpress the antibody. 24 Plasma from X7Ab HDT-treated mice stained ACKR3/CXCR7-CHO cells, confirming that HDT induced expression and secretion of X7Ab protein in vivo ( Figure 4B ). The plasma C max of X7Ab protein following HDT was four times higher than the plasma C max following injection of recombinant protein (2.4 mg/kg, a clinical dose of Rituximab), and the levels were durable, remaining elevated for >14 days, with a post-C max t 1/2 of 10 days ( Figure 4C ).
Assessment of X7Ab Safety In Vivo
Given that X7Ab binds to mouse ACKR3 protein, we utilized WT C57BL/6 mice to explore possible in vivo toxicity associated with X7Ab treatment. We injected mice with 2.4 mg/kg recombinant www.moleculartherapy.org X7Ab protein i.v. or 10 mg plasmid DNA by HDT. There was no evidence of acute toxicity immediately following injection; no differences in body weight over a 2-week period between the X7Ab treatment mice and control mice ( Figure 4D ); and no differences in general appearance or attitude. At the conclusion of the study on day 14, the mice were euthanized and major organs were weighed and examined for gross pathology. There were no differences in vital organ wet weights or appearance ( Figure 4E ). There was no evidence of overt proteinuria on day 14 ( Figure 4F ). Given the potential expression of ACKR3 by renal progenitor cells, 25 the kidneys were further evaluated for evidence of histopathology, of which none was observed ( Figure 4G ). Thus, our findings did not identify major toxicity associated with X7Ab in mice.
X7Ab-TMZ Combination Significantly Slows Cancer Progression
To assess the efficacy of X7Ab in vivo, we used orthotopic xenograft tumor models of human GBM (U343Luc and U251X7Luc) in SCID mice. ACKR3 expression is retained in vivo, as determined by X7Ab staining of resected U251X7 tumor sections ( Figure 5A ). We confirmed that X7Ab gained access to the brain during GBM tumorigenesis in vivo by quantifying antibody levels in brain/GBM homogenates following HDT injection ( Figure 5B ). In separate cohorts of GBM (U251X7Luc) xenografted mice (SCID and RAG KO), the animals were treated with X7Ab or FC-control HDT 3 and 5 weeks after tumor implantation. X7Ab treatment significantly reduced the tumor burden on week 6, as determined by quantification of total radiance (flux measured in photons/s) by in vivo imaging system (IVIS) imaging following luciferase substrate injection ( Figure 5C ). Immunodeficient mice with human GBM (U343Luc) tumors were treated with either FC-control or X7Ab DNA by HDT. Mice were imaged on weeks 3, 6, and 9. Two out of five X7Ab HDT mice showed reduced cancer progression on week 9 compared with their signal intensities on week 3 ( Figure 5D ).
We asked if combination therapy could prolong survival in vivo. SCID mice with orthotopic human GBM (U251X7Luc) tumors were treated with either X7Ab via HDT, TMZ, or the combination of X7Ab HDT and TMZ on week 3 after tumor implantation. Compared with control (huFC HDT treated) mice, only the combination therapy significantly extended survival ( Figure 5E ). The combination group had statistically significant better survival compared to all other groups: TMZ+X7 versus TMZ, *p = 0.0147; TMZ+X7 versus X7, *p = 0.0448; and TMZ+X7 versus FC-control, **p = 0.0041. Although no mice died in the combination group during the study, the tumors in the combination group eventually grew and the mice were euthanized by day 128, the humane endpoint of the experiment. The longest-lived control mouse lived 25 days less or about 20% less time than the longest-lived combination-treated mouse.
X7Ab Significantly Slows Syngeneic Mouse Glioma Progression
To assess the efficacy of X7Ab in an immunocompetent system, we used the GL261 mouse glioma model. We used 15 and 50 mg/kg TMZ as optimal survival and tumor reduction doses based on previous studies, 26 and the sub-optimal dose of 5 mg/kg TMZ in combination with X7Ab or FC-control to test the hypothesis that the combination allows us to reduce the dose of TMZ in order to lower the adverse effects associated with TMZ therapy. Using MRI, statistically significant tumor reduction was observed in mice treated with either TMZ at any dose (5, 15, and 50 mg/kg) or X7Ab (10 mg) or the combination of X7Ab + TMZ 5 mg/kg compared to the huFC only or 10% Captisol vehicle controls (Figures 6A and 6B; Movies S1, S2, S3, S4, S5, S6, S7, S8, and S9), as determined by one-way ANOVA. Decreased tumor burden correlated with increased survival ( Figure 6D ) in the survival plot of a total of 23 C57BL/6 mice inoculated with GL261 cells. The survival curve includes the control (Ctrl) group: 7 untreated, 1 treated with 10% Captisol vehicle, and 2 treated with huFC (10 mg); FC + TMZ group: 2 mice treated with huFC (10 mg) + TMZ 5 mg/kg; TMZ Tx groups: 2 mice treated with TMZ 15 mg/kg and 2 mice treated with TMZ 50 mg/kg; X7Ab group: 3 mice treated with X7Ab (10 mg); and X7Ab + TMZ group: 4 mice treated with X7Ab (10 mg) + TMZ 5 mg/kg. The survival curves (Ctrl group versus any of the treatment groups, including the double treatment group) were significantly different by log rank (MantelCox) test: ***p = 0.0092; log rank test for trend, **p = 0.0044; and Gehan-Breslow-Wilcoxon test, *p = 0.0121.
We analyzed the brain tumor microenvironment at day 28 post tumor cell inoculation by flow cytometry (Figures 6C and 6E) . By day 28, all mice with any of the X7, TMZ, or combination treatments were bright, active, and responsive, whereas the surviving FC-control mice and the 10% Captisol (vehicle control) were moribund, reaching the humane endpoint of the experiment. The samples were analyzed for presence of the relevant tumor-infiltrating leukocytes involved in tumor rejection: NK cells, NKT cells, macrophages, dendritic cells, and T cells (gating strategies, Figures S7 and S8 ). We found no significant differences among cell population numbers at this time point. However, we found that the combination of X7Ab + TMZ significantly increased the mean fluorescence intensity (MFI) of the M1 polarized macrophage population ( Figure 6E ). A similar, although not statistically significant, trend of major histocompatibility (MHC)II activation was identified on the dendritic cell population.
DISCUSSION
ACKR3 correlates with poor survival of high-grade glioma patients and, interestingly, is highly expressed in a GBM patient population refractory to treatment ( Figure 1B) . We also identified significant upregulation of ACKR3-associated molecular partners in GBM. GBM turns resistant to most cytotoxic agents, with hypoxia playing a significant role in both resistance to treatment and poor outcomes. 1 Hypoxia and other inflammatory factors that drive cell survival and stress responses upregulate ACKR3, along with many factors within the tumor and its vasculature. 27, 28 Consistent with the hypoxia link, we also found that ACKR3 falls within a hallmark hypoxia gene-set-related www.moleculartherapy.org module in weighted gene co-expression network analysis (WGCNA) of TCGA GBM samples [29] [30] [31] ( Figure S5 ). These results suggest that ACKR3-targeted immunotherapeutic intervention may be particularly beneficial for patients who respond poorly to standard of care therapy.
To determine whether ACKR3 may be a viable target for precision medicine, we generated a small chimeric antibody capable of mobilizing anti-tumor mechanisms. Previous methods to target ACKR3 consisted of small molecule targeting and single variable domain nanobodies that showed promising therapeutic effects for ACKR3+ cancers. 4, 32, 33 Compared with chemotherapy drugs or small molecules, naked mAbs have fewer off-target effects due to their increased target specificity. Antibodies activate innate immune processes, such as ADCC, CDC, and ADCP, and, due to their evolution-optimized properties, are biologically active in vivo longer. A recent study successfully targeted ACKR3+ tumors in vivo for positron emission tomography (PET) imaging using the radio-labeled antibody clone 11G8, although no therapeutic benefit was reported, 34 which is not surprising because 11G8 is a mouse IgG 1 (mIgG 1 ) isotype and therefore elicits low-level ADCC ( Figure S6 35 ).
ADCC is a major mechanism of action for many anti-cancer antibodies, with NK cells being a major contributor of cytotoxicity. ADCC depends upon interactions between the antibody FC domains and FC receptors expressed by specific leukocyte populations. Human NK cells express the A (transmembrane) isoform of CD16 (FcRIIIA). FC-mediated engagement of CD16 on NK cells leads to an activation cascade that triggers NK-driven cell lysis of antibodycoated target cells. 22, 35 Therefore, antibody efficiency is largely dependent on the interaction between the antibody FC domain and CD16 on the effector cells. 22 We demonstrate that X7Ab mediates robust ADCC. Low-grade lymphoma patients with the homozygous higher affinity (V/V) polymorphism exhibit improved clinical response rates compared with those possessing the lower affinity (V/F or F/F) polymorphism after treatment with Rituximab. Using an in vitro model of human NK-CD16 polymorphic variants, 22 we showed that X7Ab mediated NK-cell-ADCC response, regardless of the high or low affinity variant.
Consistent with other reports indicating that Rituximab kills mainly by ADCC, but also via a weaker CDC response, 36, 37 X7Ab induced a small but statistically significant CDC response against GBM cells. We used rabbit serum (reported to have strong in vitro complement activity) 38 as well as human serum effector humors. We also asked whether X7Ab has the capacity to engage macrophages because Rituximab and Herceptin also use this mechanism for cytotoxicity. 39, 40 X7Ab significantly enhanced phagocytic activity in vitro, which may have substantial and beneficial downstream effects in vivo.
In enhancing phagocytosis, X7Ab may facilitate tumor antigen presentation to the adaptive immune system, thereby helping immune recognition of tumor cells for enhanced patient response and longterm anti-tumor immunity.
Although X7Ab specifically blocked CXCL12 signaling, it did not directly induce apoptosis, implying perhaps that GBM tumor cells do not require ACKR3-dependent survival signals. On the other hand, inhibition of ligand signaling may potentially sensitize ACKR3+ cells to chemotherapeutics. In line with the observation of ACKR3 being highly expressed in a TMZ-refractory GBM patient population, we tested the hypothesis that the combination of X7Ab with TMZ, a first-line GBM treatment, would result in improved efficacy, given that the agents act via non-overlapping mechanisms. X7Ab combined with TMZ induced significantly more target GBM cell death than either agent alone via both ADCC and CDC mechanisms in vitro. Our in vitro data establish the cellular killing mechanisms employed by X7Ab (ADCC, CDC, and ADCP) to effectively mobilize anti-tumor immune effectors and kill tumor cells either alone, or, more effectively, in combination with TMZ.
An additional innovative feature of this study was the establishment of a novel platform based on HDT to enable the expression of recombinant antibodies in vivo. The method recapitulates certain aspects of virally delivered gene therapy. An advantage of HDT is that it does not require production of large amounts of recombinant protein for testing in vivo. The in vivo overexpression of antibodies by HDT (enabled by the single chain FV-FC format) may prove to be a powerful in vivo screening tool for targeted antibody development. HDT embodies aspects of passive immunity, in that the body is transiently receiving antibodies unable to undergo affinity maturation.
Although SCID mice have no T or B cells, they have active innate immunity components, including NK cells, macrophages, and a complement system. Of note, we used a suboptimal dose of TMZ in order to reduce the TMZ-associated side effects and better model patients refractory to TMZ, and this group did not have significantly improved survival. The combination group had statistically significant improved survival compared to all the other groups. The inherent leakiness of the tumor vascular endothelium likely permits our small single chain antibody to penetrate the tumor tissue. The non-overlapping mechanisms of action of X7Ab (FC receptor mediated) and TMZ (DNA damage response mechanism) work together in contributing improved survival.
The GL261 mouse glioma is a robust standardized mouse syngeneic model, with survival time for mice after GL261 cell implantation ranging from 17 to 37 days. 41, 42 Compared to the negative control groups, treatment with X7Ab alone, TMZ alone, or the combination of X7Ab with TMZ significantly inhibited tumor growth by day 21, as quantified by MRI segmentation to give tumor volumes. Although the combination of X7Ab with TMZ at the low dose of 5 mg/kg was not statistically better than TMZ alone, or X7 alone, there was a downward trend, with the combination being best at reducing tumor burden. This suggests that using X7Ab would allow us to decrease the dosage of TMZ 3-10x, thus minimizing toxic side effects.
Fluorescence-activated cell sorting (FACS) analysis at day 28 allowed in vivo post treatment analysis of the tumor microenvironment; however, it is likely that at this time point, many of the tumor-fighting cells involved in the initial therapy-mediated anti-tumor response were missed. From all the tumor-infiltrating leukocytes involved in tumor rejection (NK cells, NKT cells, macrophages, dendritic cells, and T cells) that were analyzed, only the M1 macrophages demonstrated significant differences at this time point. M1 macrophages, when polarized by expressing higher levels of MHCII, can support anti-tumor immune responses. 43 TMZ significantly increased MHCII activation, and although X7Ab increased the MHCII MFI of M1 macrophages, combining X7Ab with a low dose of TMZ at 5 mg/kg activated M1 macrophages the most. These in vivo findings suggest X7Ab can induce upregulation of MHCII expression on M1 macrophages and likely dendritic cells to potentiate the polarization/activation of innate immune cell responders to engage anti-tumor immune defenses in vivo. X7Ab may induce this effect alone, but the effect is enhanced when combined with TMZ.
In conclusion, we validated X7Ab as a tool for precision targeted immunotherapy for GBM. We show for the first time a large molecule approach to targeting ACKR3, and that as a therapeutic, it is safe and specific in mice. X7Ab utilizes a wide range of effector functions to engage the immune system to kill tumors, and combines effectively with chemotherapy to improve overall survival in GBM models. Based on this evidence, X7Ab may provide the basis for novel therapeutic interventions for improved survival in GBM patients.
MATERIALS AND METHODS
ACKR3/CXCR7 Survival Correlation and RNA Expression Determination
The survival KM plots, significance, and hazard ratios were generated using PROGgene 44 using the median mRNA expression of CXCR7 to divide patients into either high or low expression. We used mRNA microarray data from the cancer genome atlas TCGA database (https://tcga-data.nci.nih.gov/docs/publications/ tcga/?; accession date 05/30/2016). TCGA GBM level 3 data representing normalized gene-level expression signals were downloaded and analyzed using GraphPad Prism Software. The gene expression measurements were provided as the Log2 normalized ratio of expression in the tumor compared to normal brain tissue (TCGA normal organ: brain).
Cells and Reagents
U251, U343, GL261, RAW264.7, and U937 cells were obtained from the American Type Culture Collection. U251LucX7 (ACKR3 transfectants) were generated using ACKR3 plasmid DNA using lipid transfection (Lipofectamine 2000) following the manufacturer's protocol and selected by antibiotic resistance. HUVECs were obtained from Lonza, cultured per the manufacturer's specifications, and used at passage 3. The Chinese hamster ovary (CHO) cells expressing modified ACKR3 b-arrestin2 were obtained from DiscoveRx and cultured in Ham's F-12 medium (Mediatech) containing 10% fetal www.moleculartherapy.org bovine serum (FBS) (Gemini Bio-Products), penicillin/streptomycin (Mediatech), 0.3 mg/mL hygromycin (Invitrogen), and 0.8 mg/mL G-418 (Mediatech). The CD16-transduced NK-92 cell lines, 176F NK-92.05 and 176V NK-92.05, were a generous gift from Kerry S. Campbell, Fox Chase Cancer Center. CXCL12 was purchased from R&D Systems. 11G8 and isotype control mouse IgG1 was provided by ChemoCentryx (Mountain View, CA), whereas X7Ab and huFC control were generated and provided by LakePharma (Belmont, CA). TMZ, Sigma-Aldrich, was injected at 5 mg/kg intraperitoneally (i.p.) once per week for 5 weeks, starting treatment at week 3 after tumor cell implantation.
Binding Affinity (K D ) Determination for X7Ab
An Octet Qke system using anti-human FC biosensors was used to measure the kinetics of association and dissociation of X7Ab and its ACKR3 antigen (by surface-based biolayer interferometry). X7Ab (20 mg/mL) was loaded on the biosensor, and its association with various concentrations of ACKR3 antigen (300, 100, 33.3, and 11.1 nM) was measured over 180 s. Dissociation was monitored for 300 s. Reference subtraction, Savitsky Golay filtering, and global fitting of kinetic rates for the association and dissociation were performed using FortéBio analysis software.
Flow Cytometry
2.5 Â 10 5 cells were used for each staining. For unconjugated antibodies (Abs), cells were incubated with the indicated primary Abs at 4 C for 30 min in 100 mL PBS/2% FBS/2% goat serum. Cells were washed with PBS and centrifuged for 3 min at 1,200 rpm. Following the washing step, cells were incubated with secondary goat anti-mouse PE (R&D Systems) in 50 mL PBS/2% FBS/2% goat serum. For directly conjugated Abs, cells are incubated with labeled Ab at 4 C for 30 min in 100 mL PBS/2% FBS/2% goat serum. Cells were washed and centrifuged for 3 min at 1,200 rpm, resuspended, and fixed in 200 mL PBS/1% paraformaldehyde and were analyzed using a FACSCalibur (BD Biosciences, Franklin Lake, NJ).
Immunofluorescence U251X7 tumor-positive brains isolated from SCID (severe combined immunodeficiency) mice were placed in Tissue-Tek compound (Sakura) and frozen at À80 C. Cryosections of tissues fixed in 4% paraformaldehyde were stained with X7Ab or FC-control (at 10-25 mg/mL). Staining was imaged on a fluorescent microscope (Carl Zeiss) at 10x.
4 CHO-ACKR3-bgal1:b-arrestin2-bgal2 (CHO-X7) cells (DiscoveRx) were seeded into 96-well plates and cultured overnight. The next day, the medium was removed by aspiration, 100 mL of PBS containing varying concentrations of ligands was added to the wells, and the plates were incubated in 5% CO 2 at 37 C. After 90 min, 50 mL of b-galactosidase (b-gal) substrate (DiscoveRx) was added to the wells and the plates were incubated at room temperature. After 1 hr, light emission (absorbance) was analyzed in a bench top plate reader, Molecular Devices SpectraMax M5. For Ab-blocking studies, the cells were preincubated with Abs for 30 min in 5% CO 2 at 37 C, and then 5 mL of chemokine agonist was added, and the plates were processed as described.
ADCC Assay
Tumor cell line targets were labeled with CFSE (carboxyfluorescein succinimidyl ester), incubated with the indicated antibodies for 30 min, and then mixed with human PBMC, mouse splenocytes, or NK cell effectors at the indicated effector:target (E:T) ratios. The NK effector cells had been previously cultured overnight with interleukin-2 (IL-2). Propidium iodide (PI) was added to the cell mixture after 18 hr, and the cells were assessed by flow cytometry by evaluating the % of PI+ CFSE+ cells of total CFSE+ cells. For combined TMZ experiments, U251X7 cells were incubated ± TMZ (6 mM) for 5 days, labeled with CFSE, incubated ± X7Ab (100 mg/mL) for 30 min, and then mixed with human PBMC effectors at an E:T ratio of 30:1. PI was added to the cell mixture after 4 hr, and the % viable cells (PI negative) was assessed by flow cytometry by evaluating the % of PIÀ CFSE+ cells of total CFSE+ cells. The data were normalized to the average of the total number of viable targets in the untreated wells (set to 100% viable cell targets). For ADCC using SCID splenocyte effectors, U251X7 cells were incubated ± TMZ (3 mM) for 3 days, labeled with CFSE, incubated ± X7Ab (100 mg/mL) for 30 min, and then mixed with SCID mouse splenocyte effectors at an E:T ratio of 100:1. PI was added to the cell mixture after 18 hr, and the % viable cells (PI negative) was assessed by flow cytometry by evaluating the % of PIÀ CFSE+ cells of total CFSE+ cells. The data were normalized to the average of the total number of viable targets in the untreated wells (set to 100% viable cell targets).
CDC Assay
Tumor targets were incubated with the indicated antibodies for 20 min at room temperature and then mixed with rabbit or human serum (1:4 final dilution in Hank's balanced salt solution [HBSS]) for 18 hr at 37 C. CDC was assessed by flow cytometry by evaluating the percentage of PI-positive cells.
ADCP Assay
Tumor cell line targets were labeled with CFSE, incubated with the indicated antibodies for 30 min, and then mixed with effector cells, human monocyte line U937, or mouse line RAW264.7 at an E:T ratio of 5:1 for 4 hr. RAW cells were stimulated with LPS (100 ng/mL) 18 hr before use, and U937 cells were differentiated into macrophages using PMA (100 ng/mL) for 48 hr, followed by a resting period of 24 hr before use. The effector cells were labeled with an FL-4 dye. Cells were assessed by flow cytometry by evaluating the % of FL4+ CFSE+ cells as the % phagocytosed in the total population. Mice and Animal Care 6-to 8-week-old female WT C57BL/6, Rag-deficient, and BALB/c SCID mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and used for the experiments as described in the figure legends. Experiments and procedures were approved by the VAPAHCS Institutional Animal Use and Care Committee. For SCID survival studies, the mice were sacrificed when the mice reached the humane endpoint of tumor burden. MRI studies were approved by the Stanford Administrative Panel on Laboratory Animal Care and conducted at the Preclinical Imaging Core Facility at the Canary Center at Stanford for Cancer Early Detection.
Treatment In Vivo
Mice were anesthetized and tumor cells were stereotaxically injected into the striatum using a Hamilton syringe. Coordinates relative to bregma were the following: posterior = 1.95 mm, lateral = 1.75 mm, and ventral = 0.85 mm. SCID balb/c mice were injected orthotopically with $3 Â 10 5 U343 human GBM cells, and tumor progression monitored was by IVIS imaging following coelenterazine injection (i.v.). Xenografted mice were treated with either FC-control or X7Ab HDT on week 3 and imaged again on weeks 6 and 9. A total of 10 mice were xenografted with U343-Luc cells (5 treated with FC-control and 5 treated with X7Ab). The same procedure was used for implanting U251LucX7 cells. Treatment was started at 3-6 weeks after the injection of tumor cells once mice developed luciferase signals as baseline levels of tumor lesion. Tumor-bearing mice were randomized into control and treatment groups, and five to six mice were used for each experimental cohort. Mice were followed to their endpoints (30-128 days). TMZ, Sigma-Aldrich, was injected at 5 mg/kg i.p. once per week for 5 weeks, starting treatment at week 3 after tumor cell implantation. For syngeneic studies, C57BL6 immunocompetent mice were injected intracranially (i.c.) with 2 mL of GL261 cell pellet (stereotaxic injection into the frontal cortex), as described above. Control group: 7 mice with tumors but untreated, 10% Captisol was used as the TMZ vehicle control, and 2 mice were treated with huFC (10 mg) alone; FC + TMZ group: 2 mice were treated with huFC (10 mg) + TMZ 5 mg/kg; TMZ Tx groups: 2 mice were treated with TMZ 15 mg/kg and 2 mice were treated with TMZ 50 mg/kg; X7Ab group: 3 mice were treated with X7Ab (10 mg); X7Ab + TMZ group: 4 mice were treated with X7Ab (10 mg) + TMZ 5 mg/kg.
HDT
Mice were injected with either recombinant X7Ab protein i.v. (2.4 mg/kg) or 10 mg plasmid DNA by HDT on day 0. HDT was performed as previously described. 45 In brief, plasmid DNA was diluted in 2 mL physiological saline solution and injected i.v. (tail vein) in 3-5 s.
In Vivo Bioluminescence Imaging U343-Luc and U251X7-Luc glioma-bearing mice were injected i.v. with coelenterazine (15 mg/mouse). 5 min later, mice were anaesthetized and processed for image analysis using a Xenogen IVIS Lumina imaging system (Caliper, PerkinElmer) for 1-5 min. Tumor growth was imaged once a week starting on day 5 post implantation until mice reached a humane endpoint. Imaging data were analyzed and quantified with the Living Image Software for IVIS Lumina II (PerkinElmer).
Detection of X7Ab Antibody in the Brains of Mice with GBM RAG and SCID mice were injected orthotopically with $3 Â 10 5
U251X7Luc human GBM cells. Xenografted mice were left untreated or treated with X7Ab HDT on week 3 and week 5. On week 6, the mice were euthanized, exsanguinated, and perfused with 30 mL PBS. The brain and implanted tumor were removed and homogenized in 4-mL protease inhibitor buffer. Following high-speed centrifugation, the clarified extract was subjected to ELISA to detect human FC (limit of detection = 10 ng/mL).
Immunohistochemistry
Glioma and control specimens were fixed in 10% formaldehyde and embedded in paraffin. Brain sections (12 mm) were deparaffinized, and antigen retrieval was performed. After 3 washes with 1x Trisbuffered saline and Tween 20 (TBST) solution, slides were incubated at room temperature with corresponding species-specific horseradish peroxidase (HRP) conjugated secondary antibody (Dako) for 2 hr or from Vector Laboratories (1:200) for 30 min. Signal was visualized by the HRP-DAB reaction and counterstained with hematoxylin.
MRI
The mice were anesthetized in a knockdown box with 3% isoflurane, and then placed on a MRI-compatible cradle connected to a ventilator with 1.3%-1.5% isoflurane. A fiber-optic temperature probe and respiratory sensor were placed adjacent to the abdomen of the mouse. The mouse was inserted into a mouse head RF coil. The coil with the mouse was inserted to the iso-center of the magnet of a 3.0-T MR Scanner (Signa Excite HD 3T; GE Healthcare, Milwaukee, WI). Heated air was pumped into the bore to maintain the mouse body temperature at physiological levels (34 C-38 C). Morphological T1-and T2-weighted magnetic resonance whole brain images were collected using MR Solutions software (Guildford, UK), and tumor volume was quantified using region of interest (ROI) segmentation using OsiriX MD (Pixmeo, Geneva, Switzerland), where the volume from each axial slice where the tumor appeared within the brain was integrated/quantified by the ROI volume-compute volume function.
Flow Cytometry of GL261 Inoculated Mouse Brains
On day 28 post tumor cell inoculation, mice were terminated and the brains of the treatment groups and one tumor-free (normal) littermate were dissected and immediately transferred in ice-cold HBSS. Brains were digested in a buffer solution containing HBSS, Collagenase P (0.2 mg/mL), Dispase II (0.8 mg/mL), DNase I (0.01 mg/mL), and Collagenase A (0.3 mg/mL) for 60 min at 37 C under gentle rocking as described before. 41 Briefly, the digested cells were pre-incubated with rat anti-mouse FccIII/II receptor (CD16/CD32) blocking antibody for 5 min at 4 C, and then stained with the fluorochrome-conjugated We used the WGCNA package and tutorial 29, 46 to build a weighted gene co-expression network that contains 20,502 nodes (genes). The soft-threshholding power of 9 for weighted network construction was selected to maintain both the scale-free topology and sufficient node connectivity, as recommended in the WGCNA manual. We identified the modules using the advanced dynamic tree cut technique, built with the default value of SplitDepth for robust module detection in WGCNA and block-wise network construction and module detection. Genes were clustered into two blocks with a size of 10,251 genes. We then performed a full network analysis in each block separately to determine modules, represented by colors. Modules contain the gene networks. The blue module where ACKR3 was found was then submitted to Gene Set Enrichment Analysis (GSEA) (http://software.broadinstitute.org/gsea/login.jsp;jsessionid= 2759025EB5AA18A7B83495B7C8C3C49F) to determine ACKR3 gene/module biological relevance (Tables S1 and S2 ).
Statistical Analysis
All statistical significance was determined using GraphPad Prism 6 (GraphPad Software). Statistical significance was determined using unpaired two-tailed Student's t test or ANOVA in GraphPad Prism 6 (GraphPad Software), unless otherwise noted. Data are significant when p % 0.05; *p % 0.05, **p % 0.01, ***p % 0.001, and ****p % 0.0001. Sample sizes and animal numbers were chosen based on power calculations of 0.8 and pilot studies performed in the laboratory. For TCGA and ADCP multi-group analysis, significance levels were determined with GraphPad Prism 6 using grouped analysis, two-way ANOVA, and Dunnett's multiple comparisons test.
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